Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 19/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.61 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.55 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.55 |
| ▸ | MARK3 | P27448 | 2/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22818572 | 0.88 | STK17B (0.59) | TBK1PDPK1STK17AMARK3IKBKE | |
| SCHEMBL23331347 | 0.86 | TBK1 (0.50) | TBK1PDPK1STK17AMARK4MARK3 | |
| SCHEMBL22818574 | 0.86 | ULK1 (0.52) | TBK1PDPK1STK17AMARK3IKBKE | |
| SCHEMBL15188869 | 0.86 | TBK1 (0.50) | TBK1PDPK1STK17AMARK3IKBKE | |
| SCHEMBL13432001 | 0.85 | TBK1 (0.68) | TBK1PDPK1STK17AMARK4MARK3 | |
| SCHEMBL13431995 | 0.82 | TBK1 (0.65) | TBK1PDPK1STK17AMARK4MARK3 | |
| SCHEMBL1617905 | 0.82 | TBK1 (0.47) | TBK1PDPK1STK17AMARK4MARK3 | |
| SCHEMBL17162049 | 0.81 | TBK1 (0.63) | TBK1PDPK1STK17AMARK4MARK3 | |
| SCHEMBL29666237 | 0.81 | TBK1 (0.63) | TBK1PDPK1STK17AMARK4MARK3 | |
| SCHEMBL21501554 | 0.78 | TBK1 (0.55) | TBK1PDPK1STK17AMARK4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2021-05-06 | — | — | US | disclosed |
| WO-2020257180-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885PDPK1 280/4885STK17A 64/4885 |
| US-20210128556-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | TBK1 260/4885PDPK1 148/4885STK17A 548/4885 |
| US-11590134-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | TBK1 260/4885PDPK1 148/4885STK17A 548/4885 |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | TBK1 260/4885PDPK1 148/4885STK17A 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.